Herein, we used network pharmacology to reveal that TBFS treatment may improve glucocorticoid resistance in COPD through multiple signaling pathways, such as the PI3K-Akt signaling pathway. The gene discussed is AKT1; the disease is chronic obstructive pulmonary disease.